Navigation Links
NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors

Company to develop for treatment of neurofibromatosis and cancer

NEW YORK, Sept. 26 /PRNewswire/ -- NexGenix Pharmaceuticals Holdings, Inc., a privately held New York biotechnology company focused on developing drugs to treat the genetic disorder neurofibromatosis and related sporadic tumors, today announced that it has entered into a definitive agreement with Universite Louis Pasteur (ULP) and the Centre National de la Recherche Scientifique (CNRS) to in-license a novel family of Hsp90 inhibitors.

"Our preliminary evaluation of these compounds has yielded promising results in NF2 and cancer models", said Dr. Allan Rubenstein, CEO of NexGenix. "While targeting the inhibition of protein folding chaperones such as Hsp90 is an approach that is seeing success in clinical trials for cancer, this target has additionally been shown to be potentially promising for a number of therapeutic indications. We intend to evaluate this compound series for the treatment of several disorders."

Under the terms of this agreement, NexGenix will have an exclusive worldwide license to develop and commercialize the technology for human and animal therapeutic and diagnostic use from ULP and CNRS. NexGenix will be responsible for all development and commercialization costs and activities. In return, ULP and CNRS will be entitled to certain maintenance fees, milestone payments and royalties.

The company has additionally entered into a Collaborative Research Agreement with the Institut de Sciences et d'Ingenierie Supramoleculaires at ULP to further understanding of structure activity relationships and opportunities to improve the pharmacokinetic properties of the in-licensed Hsp90 inhibitor compound series. This research program is to be conducted at ULP by Nicolas Winssinger, PhD. Dr. Winssinger is one of the inventors of the compound series and is a member of the NexGenix Scientific Advisory Board.

About NexGenix Pharmaceuticals

NexGenix Pharmaceuticals is a US-based biotechnology company focused on drug development for Neurofibromatosis Types 1 and 2 and related sporadic tumors. Neurofibromatosis, or NF, is a genetic disorder characterized by the development of tumors along nerves. NexGenix has assembled a team of top NF clinicians and researchers on its Scientific Advisory Board and has developed a proprietary screening platform for both Neurofibromatosis Type 1 and 2. NexGenix will soon seek an IND for a unique treatment for NF1.

For more information, please visit the NexGenix website at The information on our website does not, however, form a part of this press release.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Certain information contained in this news release is forward-looking and is subject to unknown risks and uncertainties. The actual results, performance or achievements of the company may differ materially from the results, performance or achievements of the company expressed or implied by such forward-looking statements.

SOURCE NexGenix Pharmaceuticals Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. WARF enters licensing agreements for stem cell products
4. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
5. Software company enters health space with RFID solutions on hold
6. Lucigen Corp. enters global licensing agreement
7. Call centers and customer service: The good, the bad, and the clueless
8. GE Healthcare enters agreement with Canadian health authority
9. Data centers: Buyers beware of over-hyped facilities
10. Data centers: Blowing smoke and raising red flags
11. Prodesse enters patent agreement with Roche
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE ... has adopted a stockholder rights plan (Rights Plan) in ... operating loss carryforwards (NOLs) under Section 382 of the ... --> PharmAthene,s use of its NOLs could ... change" as defined in Section 382 of the Code. ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
(Date:11/24/2015)... 24, 2015 Cepheid (NASDAQ: CPHD ) ... the following conference, and invited investors to participate via ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ... New York, NY      Tuesday, December 1, ...
Breaking Biology Technology:
(Date:10/27/2015)... 27, 2015 In the present market scenario, ... for various industry verticals such as banking, healthcare, defense, ... growing demand for secure & simplified access control and ... as hacking of bank accounts, misuse of users, , ... as PC,s, laptops, and smartphones are expected to provide ...
(Date:10/26/2015)... and LAS VEGAS , Oct. ... Labs , an innovator in modern authentication and a ... announced the launch of its latest version of the ... enabling organizations to use standards-based authentication that supports existing ... S3 Authentication Suite is ideal for organizations deploying customer-facing ...
(Date:10/22/2015)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier of biometrics ... ended September 30, 2015.  --> ... million, a decrease of 33% compared to $6.0 million in the ... 2015 was $2.2 million, or $0.10 per diluted share, which compared ... period a year ago.  --> ...
Breaking Biology News(10 mins):